NEW YORK, September 30, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Biogen Inc. (NASDAQ: BIIB), Omeros Corporation (NASDAQ: OMER), Illumina Inc. (NASDAQ: ILMN), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research report on Arena Pharma can be accessed at https://www.equityresearchinstitute.com/ARNA.pdf On Tuesday, September 29, 2015, the NASDAQ Composite ended at 4,517.32, down 0.59%, the Dow Jones Industrial Average edged 0.30% higher, to finish the day at 16,049.13, and the S&P 500 closed at 1,884.09, up 0.12%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

Arena Pharmaceuticals Inc.'s stock plummeted 9.91%, to close the day at $1.91. The stock recorded a trading volume of 4.75 million shares, above its three months average volume of 2.70 million shares. Over the last one month and over the past three months, Arena Pharmaceuticals Inc.'s shares have lost 29.52% and 58.84%, respectively. Furthermore, the stock has declined 44.96% since the start of this year. The company's shares are trading 40.34% below their 50-day moving average. Additionally, Arena Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 21.47. Sign up and read the free notes on ARNA at:

https://www.equityresearchinstitute.com/ARNA.pdf

On Tuesday, shares in Biogen Inc. recorded a trading volume of 3.82 million shares, higher than their three months average volume of 2.73 million shares. The stock ended the day 2.19% higher at $278.23. Shares of the company traded at a PE ratio of 18.82. Biogen Inc.'s stock has declined 8.38% in the last one month, 31.12% in the previous three months and 18.04% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 11.71% and 25.49%, respectively. Furthermore, shares of Biogen Inc. have an RSI of 35.75. The complimentary notes on BIIB can be downloaded in PDF format at:

https://www.equityresearchinstitute.com/BIIB.pdf

Omeros Corp.'s stock edged 0.09% higher, to close Tuesday's session at $10.91. The stock recorded a trading volume of 1.05 million shares, below its three months average volume of 1.47 million shares. Over the last one month and the previous three months, Omeros Corp.'s shares have declined 29.61% and 39.36%, respectively. Additionally, the stock has plummeted 55.97% since the start of this year. The company is trading 28.52% and 46.02% below its 50-day and 200-day moving averages, respectively. Furthermore, Omeros Corp.'s stock has an RSI of 33.67. Register for free on Equity Research Institute and access the latest research on OMER at:

https://www.equityresearchinstitute.com/OMER.pdf

Illumina Inc.'s stock finished Tuesday's session 1.38% higher at $169.82. A total of 3.25 million shares were traded, which was above its three months average volume of 1.48 million shares. Over the last one month and the previous three months, Illumina Inc.'s shares have lost 15.81% and 22.23%, respectively. Additionally, the stock has fallen by 8.00% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 17.32% and 15.10%, respectively. Illumina Inc.'s stock traded at a PE ratio of 51.93 and has an RSI of 25.76. The complete research on ILMN is available for free at:

https://www.equityresearchinstitute.com/ILMN.pdf

On Tuesday, shares in Merrimack Pharmaceuticals Inc. ended the session 11.43% lower at $7.78. The stock reported a trading volume of 2.94 million shares, above its three months average volume of 1.41 million shares. Merrimack Pharmaceuticals Inc.'s shares have plummeted 25.86% in the last one month, 37.07% in the previous three months and 31.11% on YTD basis. The company is trading 23.04% below its 50-day moving average and 29.84% below its 200-day moving average. Moreover, shares of Merrimack Pharmaceuticals Inc. have an RSI of 26.96. Free in-depth research on MACK is available at:

https://www.equityresearchinstitute.com/MACK.pdf

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE www.equityresearchinstitute.com

Copyright 2015 PR Newswire

Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arena Pharmaceuticals Charts.
Arena Pharmaceuticals (NASDAQ:ARNA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arena Pharmaceuticals Charts.